

**CORONA Remedies Limited**

(Formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059, Gujarat, India.

Tele.: +079 - 40233000

Online at : Info@coronaremedies.com

website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

January 21, 2026

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (East), Mumbai - 400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation of our earlier intimation dated January 19, 2026 regarding receipt of Certificate of Compliance with Good Manufacturing Practice (GMP) requirements from the Eurasian Economic Union (EAEU) for finished dosage facility situated at Bhayla, Gujarat, please find enclosed herewith the press release for the same.

The press release is also being made available on the website of the Company at www.coronaremedies.com

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For **CORONA Remedies Limited**

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

CORONA Remedies Limited Secures Prestigious EAEU–GMP Certification, Strengthening Global Presence

Ahmedabad, India | January 21, 2026 — CORONA Remedies Limited proudly announces its successful accreditation with the EAEU–GMP (*Eurasian Economic Union – Good Manufacturing Practices*) certification, a significant milestone in the company’s global growth trajectory.

This certification paves the way for CORONA’s entry into five EAEU member nations— **Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan**—under a B2B business model. It unlocks access to a pharmaceutical market estimated at **USD 25 billion¹** and aligns seamlessly with CORONA’s long-term vision of fostering sustainable international partnerships.

EAEU–GMP certification further strengthens CORONA’s focus across its **four key therapeutic pillars— Women’s Health, Cardio-Diabetes, Pain Management, and Urology**.

Speaking of the occasion, **Mr. Nirav K. Mehta, CEO & Managing Director, CORONA Remedies Limited** said, *“This recognition opens new avenues for CORONA Remedies to contribute meaningfully to healthcare systems across the Eurasian region. More importantly, it reflects our core belief that quality healthcare should not be bound by geography. At CORONA, we view this as a critical step in our journey to become a trusted international partner in pharmaceutical innovation. We remain deeply committed to advancing health outcomes through sustainable, scalable, and quality-driven solutions—because our responsibility extends far beyond compliance; it is rooted in care, trust, and the well-being of communities worldwide.”*

As one of the few pharmaceutical manufacturers in Gujarat to receive this prestigious certification, CORONA underscores its operational excellence, rigorous quality systems, and adherence to global regulatory standards.

With the guiding principle of *“One World, One Quality”* CORONA continues its mission to deliver safe, effective, and trusted medicines—strengthening its footprint both in India and across the globe.

XXX

About Corona Remedies Limited

CORONA Remedies Limited is a domestic, branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other therapeutic areas. The fastest growing company among the top 30 companies in the Indian Pharmaceutical Market² in terms of domestic sales. Headquartered in Ahmedabad, Gujarat, with a strong presence across multiple therapeutic areas. The company is committed to delivering high quality, accessible healthcare solutions while actively contributing to community wellbeing through structured public health and awareness initiatives.

1: As per internal assessment

2: Pharmatrac MAT Sep’25